Apogee Therapeutics
NASDAQ: APGEFounded 2022 · 340 employees on LinkedIn · 2 known investors
Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
Founders & leadership
MH
Michael HendersoninChief Executive Officer at Apogee Therapeutics
Investors · 2
Founder mafia
2 people who came through Apogee Therapeutics went on to found or lead other companies.
Competitors · 2
by search overlapBioworld76 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Applied Therapeutics75 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Companies competing with Apogee Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Apogee Therapeutics do?
- Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
- Who are Apogee Therapeutics's investors?
- Apogee Therapeutics's investors include Access Biotechnology, RA Capital.